U.S. markets close in 5 hours 47 minutes
  • S&P 500

    3,755.96
    -27.32 (-0.72%)
     
  • Dow 30

    30,041.64
    -232.23 (-0.77%)
     
  • Nasdaq

    11,078.48
    -70.16 (-0.63%)
     
  • Russell 2000

    1,766.23
    +3.53 (+0.20%)
     
  • Crude Oil

    87.98
    +0.22 (+0.25%)
     
  • Gold

    1,720.50
    -0.30 (-0.02%)
     
  • Silver

    20.59
    +0.05 (+0.25%)
     
  • EUR/USD

    0.9828
    -0.0056 (-0.57%)
     
  • 10-Yr Bond

    3.8070
    +0.0480 (+1.28%)
     
  • GBP/USD

    1.1220
    -0.0101 (-0.89%)
     
  • USD/JPY

    144.8560
    +0.2460 (+0.17%)
     
  • BTC-USD

    20,003.32
    +132.46 (+0.67%)
     
  • CMC Crypto 200

    455.39
    -7.73 (-1.67%)
     
  • FTSE 100

    6,987.19
    -65.43 (-0.93%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

With Over 400% Upside, This Cancer Stock Offers 'Attractive Entry Point To Long-Term Investors,' Analyst Says

·1 min read
  • HC Wainwright initiated coverage on In8bio Inc (NASDAQ: INAB) with a Buy rating and a price target of $14.

  • It believes that at the current valuation of $48 million, INAB is undervalued, considering the upside potential of the company's platform.

  • The company is focused on developing γδ (gamma delta) T-cell cancer therapies.

  • The analyst views γδ T cell therapy as advantageous over conventional chimeric antigen receptor (CAR)-T cell therapy because of its excellent safety profile, combined properties of both the adaptive and innate immune systems, and its ability to treat solid tumors, including those resistant to traditional immunotherapy.

  • IN8bio's lead candidate, INB-200, is in a Phase 1 study as a therapy for newly diagnosed Glioblastoma Multiforme (GBM).

  • Related: IN8bio's Leukemia Cell Therapy Shows Durable Response.

  • HC Wainwright expects In8Bio to report initial results from the first cohort in 2022 and topline results from all cohorts in 2023.

  • The analyst notes that the company has a robust preclinical program, including INB-400, which is expected to enter the clinic in 4Q22.

  • Cell therapies are expected to enter the market in 2025 and grow to nearly $411 million risk-adjusted by 2030.

  • Price Action: INAB shares are up 34.90% at $2.67 on the last check Tuesday.

Latest Ratings for INAB

Date

Firm

Action

From

To

Jan 2022

B. Riley Securities

Maintains

Buy

Aug 2021

Mizuho

Initiates Coverage On

Buy

Aug 2021

B. Riley Securities

Initiates Coverage On

Buy

View More Analyst Ratings for INAB

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.